S
0.360
-0.01 (-1.37%)
| Previous Close | 0.365 |
| Open | 0.380 |
| Volume | 129,576 |
| Avg. Volume (3M) | 1,322,047 |
| Market Cap | 150,560,928 |
| Price / Sales | 34.40 |
| Price / Book | 8.92 |
| 52 Weeks Range | |
| Earnings Date | 20 Aug 2025 - 25 Aug 2025 |
| Operating Margin (TTM) | -222.17% |
| Diluted EPS (TTM) | -0.030 |
| Quarterly Revenue Growth (YOY) | -69.80% |
| Total Debt/Equity (MRQ) | 10.68% |
| Current Ratio (MRQ) | 5.41 |
| Operating Cash Flow (TTM) | -11.07 M |
| Levered Free Cash Flow (TTM) | -6.33 M |
| Return on Assets (TTM) | -21.28% |
| Return on Equity (TTM) | -43.47% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (AU) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | STARPHARMA FPO [SPL] | - | - |
AIStockmoo Score
-0.5
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 0.5 |
| Average | -0.50 |
|
Starpharma Holdings Ltd is an Australia-based company engaged in the research, development, and commercialization of dendrimer products for pharmaceutical, life science, and other applications. It focuses on the development of VivaGel for the management and prevention of bacterial vaginosis and as a condom coating and VIRALEZE an antiviral nasal spray. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 20.27% |
| % Held by Institutions | 23.61% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |